var data={"title":"Prevention of herpes simplex virus type 1 infection in immunocompetent patients","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Prevention of herpes simplex virus type 1 infection in immunocompetent patients</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/contributors\" class=\"contributor contributor_credentials\">Robyn S Klein, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 15, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Herpes simplex virus type 1 (HSV-1) may cause gingivostomatitis, which is characterized by vesiculoulcerative lesions of the oral mucosa. Reactivation of HSV-1 occurs in the trigeminal sensory ganglion and may lead to herpes labialis (eg, &quot;cold sores&quot;), which often occurs along the vermillion border of the lip.</p><p>The prevention of HSV-1 infections will be reviewed here. The clinical manifestations and treatment of primary and episodic recurrent HSV infections are discussed elsewhere. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;</a> and <a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">&quot;Treatment of herpes simplex virus type 1 infection in immunocompetent patients&quot;</a>.)</p><p>The treatment and prophylaxis of HSV-1 infections in the immunocompromised patient are discussed elsewhere. (See <a href=\"topic.htm?path=prevention-of-infections-in-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">&quot;Prevention of infections in hematopoietic cell transplant recipients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PREVENTIVE VACCINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is currently no effective vaccine against HSV-1 infection [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/1\" class=\"abstract_t\">1</a>].</p><p>In recurrent cutaneous HSV-1 infection, there is a sequential infiltrate of CD4+ and then CD8+ T lymphocytes into lesions. CD4 lymphocytes produce intralesional IFN-gamma and recognize the structural proteins of HSV (ie, glycoproteins D and B) when restimulated in vitro. Research on the immunodominant epitopes of these two glycoproteins may help inform future vaccine trials in humans [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">AVAILABLE ANTIVIRAL AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antiviral agents for HSV infection include <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, and <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>; metabolites of these nucleoside derivatives interfere with the synthesis of viral DNA [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/4\" class=\"abstract_t\">4</a>]. Of all the human herpesviruses, acyclovir has the greatest in vitro activity against HSV-1 and HSV-2. The triphosphate form of acyclovir inhibits viral DNA polymerase.</p><p><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> and <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> have greater oral bioavailability than <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/5\" class=\"abstract_t\">5</a>] and are dosed less frequently, but are generally more expensive. The margin of safety and tolerability of all three medications is excellent since these medications are selectively converted to active compounds within virally infected cells. Acyclovir is the only medication of this group that can be dosed intravenously. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a> and <a href=\"topic.htm?path=valacyclovir-an-overview\" class=\"medical medical_review\">&quot;Valacyclovir: An overview&quot;</a> and <a href=\"topic.htm?path=famciclovir-an-overview\" class=\"medical medical_review\">&quot;Famciclovir: An overview&quot;</a>.)</p><p>Topical <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> and topical <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> have also been studied for recurrent herpes labialis [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/4\" class=\"abstract_t\">4</a>]. Topical treatment with each of these agents requires frequent daily applications (acyclovir five times a day or penciclovir nine times a day). (See <a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">&quot;Treatment of herpes simplex virus type 1 infection in immunocompetent patients&quot;</a>.)</p><p>Dosing regimens and duration for prophylaxis of HSV-1 infections are not well established.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">PROPHYLAXIS FOR RECURRENT HSV WITH IDENTIFIED TRIGGER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both iatrogenic and natural triggers can lead to predictable HSV-1 infections in some patients [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/6-10\" class=\"abstract_t\">6-10</a>]. Treatment trials have addressed a variety of strategies of managing these patients.</p><p>Management of sporadic recurrent HSV-1 infection is discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">&quot;Treatment of herpes simplex virus type 1 infection in immunocompetent patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Sunlight exposure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients have well-documented triggers (eg, intense sunlight exposure) leading to HSV-1 reactivation [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Various treatment strategies have been evaluated to prevent these recurrences, including sunscreen and topical and oral antiviral therapies. No studies have directly compared any of these strategies.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Sunscreen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A placebo-controlled crossover trial of 38 patients showed that after ultraviolet (UV) light exposure, herpes labialis developed in 27 patients (71 percent) treated with placebo with a mean time to HSV recurrence of 2.9 days [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/11\" class=\"abstract_t\">11</a>]. In contrast, when sunscreen was applied before UV light exposure, no lesions developed, although 1 of the 35 patients shed virus at the exposure site.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Topical therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Placebo-controlled trials of topical antiviral creams have shown conflicting results as to whether treatment decreases the risk of recurrence in patients with light-induced herpes labialis [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Oral antiviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are conflicting data on the benefit of antiviral therapy in patients with a well-recognized trigger for HSV reactivation.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A randomized trial was performed among 237 skiers with a history of recurrent labial herpes triggered by sun exposure to determine if <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> could lead to a lower frequency of HSV reactivation or faster lesion resolution [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/6\" class=\"abstract_t\">6</a>]. Oral acyclovir (800 mg twice daily) was initiated 12 to 24 hours before sun exposure and continued for three to seven days. Patients in the treatment arm did not have any clinical benefit compared with those in the placebo arm.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another trial, 147 skiers with a history of sun-induced recurrences of HSV-1 were treated prophylactically with oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> or matching placebo and were observed during their ski holidays [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/14\" class=\"abstract_t\">14</a>]. This study demonstrated a clinical benefit of acyclovir prophylaxis; 5 (7 percent) of 75 acyclovir-treated subjects developed lesions compared with 19 (26 percent) of 72 persons in the placebo group.</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Surgical procedures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients with a history of HSV infection, herpes labialis occurs in approximately 50 to 70 percent of patients undergoing trigeminal nerve root decompression or facial dermabrasion [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/15-17\" class=\"abstract_t\">15-17</a>] and in 10 to 15 percent of patients undergoing dental extractions [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/18,19\" class=\"abstract_t\">18,19</a>]. There are conflicting data as to whether dental surgery leads to an increase in asymptomatic viral shedding [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/20,21\" class=\"abstract_t\">20,21</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a controlled trial of 30 patients, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> initiated the night before trigeminal surgery at 400 mg twice daily for five days led to a high degree of protection against HSV reactivation; 1 of 14 patients had an episode of HSV infection compared with 12 of 16 among the placebo recipients [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/22\" class=\"abstract_t\">22</a>]. Of note, no selection for prior herpes labialis infections or presence of antibodies to HSV was required for participation in the trial. At day three after surgery, HSV-positive cultures were demonstrated in 12 of 16 placebo recipients versus 3 of 14 patients on the treatment arm.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No episodes of HSV reactivation were seen among 84 patients undergoing dermabrasion who initiated prophylaxis with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (500 mg BID for 14 postoperative days) over the 21-day period of observation; however, the study did not include a placebo arm for comparison [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p>We suggest use of antiviral prophylaxis for patients who are undergoing trigeminal nerve root decompression or facial dermabrasion. The optimal regimen and duration of treatment are unknown.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">HSV-ASSOCIATED ERYTHEMA MULTIFORME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary and recurrent HSV infections have also been associated rarely with the development of erythema multiforme (EM). HSV antigen has been demonstrated in skin lesion biopsy samples from such patients [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/5\" class=\"abstract_t\">5</a>].</p><p>The optimal management of such patients is unknown. In one study of patients with childhood HSV-associated erythema multiforme, treatment with topical <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> or oral acyclovir (25 <span class=\"nowrap\">mg/kg</span> per day) was not effective in decreasing the duration of the EM lesions, which lasted a mean of 11 days [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/5\" class=\"abstract_t\">5</a>]. These data suggest that a better approach to these patients may be the use of chronic suppressive therapy, which means daily administration of an antiviral agent, such as acyclovir.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PREVENTION OF HSV IN HEALTH CARE WORKERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Health care providers should use gloves during physical examination of a patient with active HSV lesions to prevent personal acquisition of HSV infection.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">PREVENTION OF SEXUAL TRANSMISSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although HSV-1 has a particular tropism for mucosal and cutaneous skin sites, it can also cause genital ulcer disease. Indeed, half of new cases of genital lesions in the developed world are caused by HSV-1 [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/24\" class=\"abstract_t\">24</a>]. </p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Transmission of HSV-1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with oral HSV infection (primary or recurrent) should be educated that they can transmit HSV-1 through oral sex to their uninfected partner resulting in genital ulcers [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/25\" class=\"abstract_t\">25</a>]. This issue may be particularly important if their HSV-negative partner is pregnant. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection&quot;</a> and <a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy\" class=\"medical medical_review\">&quot;Genital herpes simplex virus infection and pregnancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Condom use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whether condom use is effective against all sexual transmission of HSV-1 has not been evaluated. However, studies of HSV-2 indicate that proper condom usage may prevent up to half of sexually transmitted cases of genital herpes [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/18,26-28\" class=\"abstract_t\">18,26-28</a>]. As an example, a large, pooled prospective analysis of partner transmission of HSV-2 among 528 discordant couples was performed to assess the role of condom use in prevention of infection [<a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/18\" class=\"abstract_t\">18</a>]. The results demonstrated moderate protection against HSV-2 transmission in women when condoms were used during more than 25 percent of sex acts. (See <a href=\"topic.htm?path=prevention-of-sexually-transmitted-infections\" class=\"medical medical_review\">&quot;Prevention of sexually transmitted infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Antiviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> is effective against transmission of genital HSV-2 infection in discordant couples, but its role in the prevention of sexual transmission of HSV-1 infection has not been studied. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no available vaccine for the prevention of HSV-1 infection. (See <a href=\"#H2\" class=\"local\">'Preventive vaccine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest the use of prophylactic sunscreen in patients with a history of light-induced reactivation of HSV infection (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H4\" class=\"local\">'Prophylaxis for recurrent HSV with identified trigger'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with a history of HSV infection, herpes labialis occurs in approximately 50 to 70 percent of patients undergoing trigeminal nerve root decompression or facial dermabrasion and in 10 to 15 percent of patients undergoing dental extractions. (See <a href=\"#H4\" class=\"local\">'Prophylaxis for recurrent HSV with identified trigger'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest use of antiviral prophylaxis for patients who are undergoing trigeminal nerve root decompression (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We also suggest antiviral prophylaxis for patients with a history of recurrent herpes labialis who are undergoing facial dermabrasion (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H4\" class=\"local\">'Prophylaxis for recurrent HSV with identified trigger'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with oral HSV infection (primary or recurrent) should be educated that they can transmit HSV-1 through oral sex to their uninfected partner resulting in genital ulcers. (See <a href=\"#H12\" class=\"local\">'Prevention of sexual transmission'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/1\" class=\"nounderline abstract_t\">Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest 2002; 110:145.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/2\" class=\"nounderline abstract_t\">Kim M, Taylor J, Sidney J, et al. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol 2008; 181:6604.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/3\" class=\"nounderline abstract_t\">Chentoufi AA, Zhang X, Lamberth K, et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 2008; 180:426.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/4\" class=\"nounderline abstract_t\">Kesson AM. Use of aciclovir in herpes simplex virus infections. J Paediatr Child Health 1998; 34:9.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/5\" class=\"nounderline abstract_t\">Weston WL, Morelli JG. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med 1997; 151:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/6\" class=\"nounderline abstract_t\">Raborn GW, Martel AY, Grace MG, McGaw WT. Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85:55.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/7\" class=\"nounderline abstract_t\">Spruance SL, Rowe NH, Raborn GW, et al. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999; 179:303.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/8\" class=\"nounderline abstract_t\">Spruance SL, Freeman DJ, Stewart JC, et al. The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J Infect Dis 1991; 163:728.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/9\" class=\"nounderline abstract_t\">Gilbert SC. Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study. J Drugs Dermatol 2007; 6:400.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/10\" class=\"nounderline abstract_t\">Mills J, Hauer L, Gottlieb A, et al. Recurrent herpes labialis in skiers. Clinical observations and effect of sunscreen. Am J Sports Med 1987; 15:76.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/11\" class=\"nounderline abstract_t\">Rooney JF, Bryson Y, Mannix ML, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet 1991; 338:1419.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/12\" class=\"nounderline abstract_t\">Evans TG, Bernstein DI, Raborn GW, et al. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002; 46:1870.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/13\" class=\"nounderline abstract_t\">Bernstein DI, Schleupner CJ, Evans TG, et al. Effect of foscarnet cream on experimental UV radiation-induced herpes labialis. Antimicrob Agents Chemother 1997; 41:1961.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/14\" class=\"nounderline abstract_t\">Spruance SL, Hamill ML, Hoge WS, et al. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA 1988; 260:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/15\" class=\"nounderline abstract_t\">Wall SH, Ramey SJ, Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg 1999; 104:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/16\" class=\"nounderline abstract_t\">Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999; 25:242.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/17\" class=\"nounderline abstract_t\">Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/18\" class=\"nounderline abstract_t\">Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009; 169:1233.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/19\" class=\"nounderline abstract_t\">Openshaw H, Bennett HE. Recurrence of herpes simplex virus after dental extraction. J Infect Dis 1982; 146:707.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/20\" class=\"nounderline abstract_t\">Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. Oral Dis 2007; 13:414.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/21\" class=\"nounderline abstract_t\">Marques-Silva L, Castro WH, Gomez EL, et al. The impact of dental surgery on HSV-1 reactivation in the oral mucosa of seropositive patients. J Oral Maxillofac Surg 2007; 65:2269.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/22\" class=\"nounderline abstract_t\">Sch&auml;delin J, Schilt HU, Rohner M. Preventive therapy of herpes labialis associated with trigeminal surgery. Am J Med 1988; 85:46.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/23\" class=\"nounderline abstract_t\">Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. Dermatol Surg 2000; 26:50.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/24\" class=\"nounderline abstract_t\">Glin&scaron;ek Bi&scaron;kup U, Ur&scaron;i&#269; T, Petrovec M. Laboratory diagnosis and epidemiology of herpes simplex 1 and 2 genital infections. Acta Dermatovenerol Alp Pannonica Adriat 2015; 24:31.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/25\" class=\"nounderline abstract_t\">Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30:797.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/26\" class=\"nounderline abstract_t\">Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/27\" class=\"nounderline abstract_t\">Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006; 194:42.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients/abstract/28\" class=\"nounderline abstract_t\">Magaret AS, Mujugira A, Hughes JP, et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis 2016; 62:456.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8287 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H16\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PREVENTIVE VACCINE</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">AVAILABLE ANTIVIRAL AGENTS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">PROPHYLAXIS FOR RECURRENT HSV WITH IDENTIFIED TRIGGER</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Sunlight exposure</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Sunscreen</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Topical therapy</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Oral antiviral therapy</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">Surgical procedures</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">HSV-ASSOCIATED ERYTHEMA MULTIFORME</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">PREVENTION OF HSV IN HEALTH CARE WORKERS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">PREVENTION OF SEXUAL TRANSMISSION</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Transmission of HSV-1</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Condom use</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Antiviral therapy</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">Acyclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of herpes simplex virus type 1 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=famciclovir-an-overview\" class=\"medical medical_review\">Famciclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy\" class=\"medical medical_review\">Genital herpes simplex virus infection and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-infections-in-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">Prevention of infections in hematopoietic cell transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-sexually-transmitted-infections\" class=\"medical medical_review\">Prevention of sexually transmitted infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Treatment of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">Treatment of herpes simplex virus type 1 infection in immunocompetent patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=valacyclovir-an-overview\" class=\"medical medical_review\">Valacyclovir: An overview</a></li></ul></div></div>","javascript":null}